1
1Torrent Pharma has made a significant advancement in diabetes treatment with the launch of India’s first oral semaglutide. This innovative drug is set to revolutionize the management of diabetes, offering a new option for patients who prefer oral medication over injections.
Semaglutide is a GLP-1 receptor agonist, a class of medications that helps regulate blood sugar levels. It works by increasing insulin secretion and reducing glucagon release, making it an effective solution for individuals with type 2 diabetes.
The newly launched oral semaglutide provides an alternative to the injectable version, making it easier for patients to adhere to their treatment plans. The injectable form is priced at ₹3,999 per month, making it accessible for a larger segment of the population.
With the introduction of oral semaglutide, Torrent Pharma is entering a competitive landscape where other companies like Sun Pharma, Dr. Reddy’s, and Zydus are also rolling out their generic versions of semaglutide. The recent patent expirations have led to a drastic reduction in prices, with some generic options available for as low as ₹3,000.
The primary advantage of oral semaglutide is its ease of use. Patients no longer need to fear needles, which can be a significant barrier for many. This shift aims to improve patient adherence and overall health outcomes.
Patients interested in this new medication can consult their healthcare providers to determine if oral semaglutide is suitable for their treatment plan. Additionally, it is essential to discuss potential side effects and how this medication fits into a comprehensive diabetes management strategy.
Torrent Pharma’s launch of India’s first oral semaglutide marks a pivotal moment in diabetes treatment. By offering a more convenient and user-friendly option, the company aims to improve the lives of millions affected by diabetes across the country.
Semaglutide is a GLP-1 receptor agonist used to manage blood sugar levels in patients with type 2 diabetes.
The injectable form is priced at ₹3,999 per month, while generic options may be available for as low as ₹3,000.
The primary benefit is its ease of use, eliminating the need for injections and improving patient adherence.